检索结果-南通市图书馆

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer

引用

Cancer Communications 2023年第8期43卷 943-946页

作者： François Bertucci alexandre de nonneville Pascal Finetti Emilie Mamessier11Laboratory of Predictive Oncology Label Team“Ligue contre le cancer”Cancer Research Center of MarseillePaoli-Calmettes InstituteAix-Marseille UniversityInserm UMR1068CNRS UMR725MarseilleFrance department of Medical Oncology Paoli-Calmettes InstituteMarseilleFrance

dear Editor,Pembrolizumab,an immune checkpoint inhibitor(ICI),was recently approved for early-stage triple-negative breast cancer(eTNBC),and promising results have been reported in advanced hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-)and HER2+BCs[1].Given the costs and potential toxicity,markers predictive of ICI benefits are ***,neither programmed death-ligand 1(PD-L1)expression nor other tested markers(i.e.,tumor mutational burden,microsatellite instability)effectively predict ICI benefit[2].Tertiary lymphoid structures(TLS)are secondary lymphoid organ-like aggregates that reside in the tumor microenvironment and are associated with clinical response to ICIs in metastatic melanoma,renal cell carcinoma.

关键词： lymphoid breast cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Monarch Etrial:improving the clinical outcome in HR^(+)/HER2^(−)early breast cancer:recent results and next steps

引用

Cancer Communications 2023年第8期43卷 938-942页

作者： François Bertucci Pascal Finetti Emilie Mamessier alexandre de nonneville Laboratory of Predictive Oncology Cancer Research Center of MarseillePaoli-Calmettes InstituteAix-Marseille UniversityINSERM UMR1068CNRS UMR725Team Labelled“Ligue contre le cancer”MarseilleFrance department of Medical Oncology Paoli-Calmettes InstituteMarseilleFrance

Breast cancer(BC)is the most frequent cancer in women worldwide,and hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR^(+)/HER2^(−))is the most frequent BC *** adjuvant systemic treatment of HR^(+)/HER2^(−)early-stage BC(eBC),based on prognostic factors[1],sometimes includes chemotherapy,and in most cases,it includes endocrine therapy(ET).In the past decade,advancements in ET,such as successive approvals of tamoxifen and aromatase inhibitors and the extension of ET duration to 10 years in high-risk patients.

关键词： HER2 cancer chemotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The safety and efficacy of palbociclib in older patients with advanced breast cancer in a real-world setting

引用

Journal of Cancer Metastasis and Treatment 2022年第1期8卷 15-27页

作者： Etienne Gouton Louis Tassy Joëlle Micallef Amir Meskine Renaud Sabatier Maud Cecile-Herry Cécile Braticevic Anthony Goncalves Frederic Viret alexandre de nonneville Coline Montegut Franck Rouby Frederique Rousseau department of Medical Oncology Institut Paoli-CalmettesMarseille 13009France Aix-Marseille Univ CNRS U7258INSERM U1068Institut Paoli-CalmettesCRCMMarseille 13009France department of Clinical Pharmacology Régional Center of Pharmacovigilance Marseille-Provence-CorseAssistance Publique-Hôpitaux de MarseilleAix-Marseille Univ.Neurosciences InstituteMarseille 13005France

Aims:Palbociclib has been approved in combination with endocrine therapy(ET)for hormone receptor-positive(HR+)/human epidermal growth factor receptor 2-negative(HER2-)advanced breast cancer(ABC),regardless of *** though ABC is one of the most prevalent cancers in older patients,very few patients≥65 years old were included in pivotal ***,the current study evaluated the safety and efficacy of palbociclib in“real-world”routine treatment of unselected older patients with HR+/***:Data were collected on patients>70 years old who were treated with palbociclib plus ET for HR+/HER2-ABC in our *** analyzed safety data(CTCAE v4.0 criteria)and outcomes,such as progression-free survival(PFS)and overall survival(OS),as well as any associations between main geriatric characteristics and our ***,we assessed safety at a national level by analyzing all palbociclib-related adverse events(AEs)reported in the French Pharmacovigilance Database(FPVD)during the same ***:From February 2016 to July 2019,52 patients were identified with a median age of 80.9 years,of whom 88%presented an *** most common grade 3-4 AE was neutropenia(64%).Median PFS and OS were nine months and not reached,*** FPVD reports 227 cases of palbociclib-related AEs,with older and younger patients sharing similar ***:Palbociclib is well tolerated in older patients with efficacy comparable to that in younger ***,the addition of palbociclib to ET should be evaluated individually in this older and frailer subgroup.

关键词： Advanced breast cancer palbociclib older patients tolerance efficacy pharmacovigilance

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：